ClinicalTrials.gg
TerminatedNCT06603246Updated Oct 20, 2026

A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease

A Phase 1 interventional study of GDC-6988 in Non-cystic Fibrosis Bronchiectasis and Chronic Obstructive Pulmonary Disease, sponsored by Genentech, Inc.. Terminated at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Sponsor's Decision
Updated Oct 20, 2026Now TerminatedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche — 1 open to participants now, 2 under way, 1 of them phase 3. Pulmonary Disease, Chronic Obstructive · Hoffmann-La Roche.

Started
2024
the only one that year
Phase 1
2 of 10
none open now
Registered
8th of 10
by date

Among the 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche, this one is the only one that started in 2024, is one of 2 in phase 1, and was the 8th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This study evaluates the safety, tolerability, and activity of inhaled GDC-6988 in participants with muco-obstructive disease.

03

Conditions studied

  • Non-cystic Fibrosis Bronchiectasis
  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Percent predicted ≥ 40% by spirometry during screening
  • Ability to demonstrate correct use of the smart DPI at screening, in the investigator's judgment
  • On a stable treatment regimen for muco-obstructive diseases for ≥ 28 days prior to initiation of study treatment and willingness to remain on the stable treatment regimen through completion of study
  • Stable disease for ≥ 28 days prior to screening and through to initiation of study treatment

Additional Inclusion Criteria for Participants in Part B

  • Chronic sputum production of ≥1 teaspoon per day as reported in the sputum volume item
  • Ability to produce a sputum sample that is suitable for central laboratory determination of mucus percent solids and sialic acid concentration exploratory biomarker research, and biomarker assay development
  • Availability of a representative blood sample for exploratory biomarker research and biomarker assay development

Additional Inclusion Criteria for Participants With Non-cystic Fibrosis Bronchiectasis (NCFB) (Cohort 1, Cohort 2, and Cohort 3):

- Diagnosis of bronchiectasis on the basis of prior chest computed tomography (CT), involving at least 2 lobes, with at least one lobe of involvement in the right lung as assessed by the investigator

Additional Inclusion Criteria for Participants With (COPD) (Cohort 1, Cohort 2, and Cohort 4):

  • COPD defined as post-bronchodilator FEV1/FVC ratio of \<0.7
  • Chronic bronchitis, with a definition including chronic cough and excessive sputum production for more than 3 months per year for at least 2 years prior to screening
  • Former smoker with a minimum of 10 pack-year history (e.g., 20 cigarettes/day for 10 years) or non-smoker with at least one documented COPD risk factor

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding, or intention of becoming pregnant during the study or within the timeframe in which is required
  • Known significant bronchodilator response of >10% predicted change in or FVC, in the investigator's judgment
  • Use of any prohibited medications
  • Acute respiratory infection within 28 days of screening
  • Significant hemoptysis greater than 60 milliliter (mL) within 3 months prior to screening
  • Known immunodeficiency that, in the investigator's judgment, is and places the individual at a substantially elevated risk for opportunistic infections.
  • Known substance abuse, in the investigator's judgment, within 12 months prior to screening
  • Poor peripheral venous access
  • Receipt of blood products within 120 days prior to screening
  • Any medical condition or abnormal clinical laboratory finding that, in the investigator's judgment, would preclude the individual's safe participation in and completion of the study or could affect the interpretation of the results
  • History of thoracic or within 5 years prior to screening
  • Known history of a clinically significant abnormal (ECG), or presence of an abnormal ECG that is deemed clinically significant by the investigator
  • corrected through use of Fridericia's formula (QTcF) >450 milliseconds (ms) for males or >470 ms for females

Additional Exclusion Criteria for Participants in Part B -More than 2 chest CTs or other procedures known to expose the lungs to greater than 100 millisievert (mSv) within 12 months prior to screening

Additional Exclusion Criteria for Participants With NCFB (Cohort 1, Cohort 2, and Cohort 3)

  • Bronchiectasis primarily due to cystic fibrosis, primary ciliary dyskinesia, non-tuberculous mycobacterial infection, chronic aspiration, or predominantly traction bronchiectasis due to interstitial lung disease (ILD), in the investigator's judgment
  • Diagnosis of asthma, that in the investigator's judgment, is the primary driver of the individual's respiratory disease (e.g., primary asthma with incidental bronchiectasis findings)
  • NCFB exacerbation within 28 days prior to screening or that has not returned to baseline
  • Current smoker: Current smoking is defined as any use of inhaled tobacco products or inhaled marijuana within 3 months prior to screening, through use of cigarettes, cigars, electronic cigarettes, vaporizing devices, or pipes.

Additional Exclusion Criteria for Participants with NCFB in Cohort 3

- Diagnosis of that, in the investigator's judgment, is the primary driver of the individual's respiratory disease (e.g., primary COPD with incidental bronchiectasis findings)

Additional Exclusion Criteria for Participants With COPD (Cohort 1, Cohort 2, and Cohort 4):

  • COPD exacerbation within 28 days prior to screening or that has not returned to baseline
  • Asthma/COPD overlap syndrome
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    GDC-6988

    Participants in Cohort 1 will receive low-dose GDC-6988, twice a day (BID) on Day 1, followed by high-dose, BID on Day 2. Participants in Cohort 2 will receive low-dose, followed by high-dose GDC-6988, BID for 14 days. Participants in Cohorts 3 and 4 will receive low-dose GDC-6988, BID for 14 days.

    Drug: GDC-6988

Interventions

  • DrugGDC-6988

    GDC-6988 will be administered using a dry powder inhalation (DPI) device.

    Also known as: RO7506811

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events (AEs), with Severity Assessed by Division of Acquired Immunodeficiency Syndrome (DAIDS) Toxicity Grading Scale

    The AEs will be graded according to the DAIDS table for grading the severity. The severity level is graded from Grade 1 (mild) to 4 (Potentially Life-Threatening).

    Time frame: From baseline up to 6 weeks

  2. Percentage of Participants With Spirometry Abnormalities

    Time frame: From baseline up to 6 weeks

Secondary outcomes

  1. Part A: Percentage of Participants With Spirometry Abnormalities Without and With Albuterol Pretreatment

    Spirometric abnormalities related to forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and maximal (peak) inspiratory flow rate, and flow-volume loops will be reported.

    Time frame: From baseline up to 6 weeks

  2. Plasma Concentration of GDC-6988 at Specified Timepoints

    Other relevant pharmacokinetic (PK) parameters may be assessed.

    Time frame: Part A: Day 1 and Day 2, Part B: Day 1, Day 8 and Day 15

  3. Part B: Change From Baseline in Sputum Percent Solids at Day 8 and Day 14

    Time frame: Baseline, at Day 8 and at Day 14

  4. Part B: Change From Baseline in Whole-lung Mucociliary Clearance (MCC) Scintigraphy at Day 8

    Time frame: Baseline and at Day 8

  5. Part B: Change From Baseline in Sputum Percent Solids at Day 15

    Time frame: Baseline and at Day 15

  6. Part B: Change From Baseline in Whole-lung MCC Scintigraphy at Day 15

    Time frame: Baseline and at Day 15

07

Study locations

6 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Stanford Center for Excellence in Pulmonary Biology
    Palo Alto, California 94304, United States
  • University of Kansas Medical Center-Kansas City-3901 Rainbow Blvd
    Kansas City, Kansas 66160 8500, United States
  • University of North Carolina Clinical Research Center
    Chapel Hill, North Carolina 27514, United States
  • UPMC Montefiore Hospital
    Pittsburgh, Pennsylvania 15213 3236, United States
  • TTS Research
    Boerne, Texas 78006, United States
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Nov 2024 to primary completion in Aug 2026, 21 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Nov 2027 → Aug 2026 and completion Nov 2027 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2024
First posted
Sep 19, 2024
StartActual
Nov 18, 2024
Primary completionActual
Aug 18, 2026was Nov 2027
CompletionActual
Aug 18, 2026was Nov 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Sponsor's Decision
changed Oct 20, 2026
Sites
1 site removed
Show 1 removed
  • Accel Research Site - Achieve - Birmingham - ERN - PPDS · Vestavia Hills, United States
Oct 20, 2026
Primary completion
Nov 15, 2027→Aug 18, 2026 (actual)
Oct 20, 2026
Study completion
Nov 15, 2027→Aug 18, 2026 (actual)
Oct 20, 2026
Enrollment
128 (estimated)→17 (actual)
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Recruiting→Terminated
    Why stopped Sponsor's Decision
    1 site removed
    Show 1 removed
    • Accel Research Site - Achieve - Birmingham - ERN - PPDS · Vestavia Hills, United States
    Primary completion Nov 15, 2027→Aug 18, 2026 (now actual)
    Study completion Nov 15, 2027→Aug 18, 2026 (now actual)
    Enrollment 128 (estimated)→17 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06603246
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Nov 18, 2024
Primary completion
Aug 18, 2026
Completion
Aug 18, 2026
Last update
Oct 20, 2026

Study contacts

Clinical Trials
study director · Genentech, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion